Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07512284 · ClinicalTrials.gov registry record · Phase 2

Mindfulness Engaged Neurostimulation for Depression (MEND II)

A Phase 2 study, sponsored by University of California, San Diego.

Recruiting
Registry status
Phase 2
Development phase
120
Enrollment target

NCT07512284 is a Phase 2 study that is actively recruiting participants, run by University of California, San Diego. The registered enrollment target is 120 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07512284, a Phase 2 study, is actively recruiting participants, sponsored by University of California, San Diego.

RECRUITING
Registry status
Phase 2
Development phase
120 participants
Enrollment target

Study Summary

Repetitive Transcranial Magnetic stimulation (rTMS) is an FDA-approved therapy for treatment resistant depression (TRD) that involves brief magnetic stimulation pulses on the dorsolateral prefrontal cortex (DLPFC) brain region. But studies of rTMS alone show remission rates of \~30%. Additionally, rTMS has not been shown to improve cognitive functioning that may be an independent factor predicting treatment success. This study will develop a novel multimodal treatment, which combines intermittent theta burst stimulation (iTBS) - a type of rTMS with digital mindfulness training to engage brain plasticity, enhance cognition and alleviate depression symptoms in individuals with TRD.

Interventions

  • COMBINATION_PRODUCT Medi-TBS

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2026-05-01
Est. Completion 2029-04-30
Phase Phase 2

Sponsor

University of California, San Diego

775 total trials

What the Registry Record Tells You About NCT07512284

The ClinicalTrials.gov registry entry for NCT07512284 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Medi-TBS is the first listed.

NCT07512284 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT07512284 about?

NCT07512284 is a clinical study titled "Mindfulness Engaged Neurostimulation for Depression (MEND II)". Repetitive Transcranial Magnetic stimulation (rTMS) is an FDA-approved therapy for treatment resistant depression (TRD) that involves brief magnetic stimulation pulses on the dorsolateral prefrontal cortex (DLPFC) brain region. But studies of rTMS alone show remission rates of \~30%. Additionally, r...

What is the current status of trial NCT07512284?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2026-05-01. Estimated completion is 2029-04-30.

What interventions are being tested in trial NCT07512284?

The interventions under investigation include: Medi-TBS (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT07512284?

This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.